Immunocore Holdings Limited (IMCR)
| Market Cap | 1.52B |
| Revenue (ttm) | 28.08M |
| Net Income (ttm) | n/a |
| Shares Out | 43.79M |
| EPS (ttm) | -4.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 44,753 |
| Open | 35.80 |
| Previous Close | 35.81 |
| Day's Range | 34.54 - 35.81 |
| 52-Week Range | 27.77 - 61.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 52.00 (+49.6%) |
| Est. Earnings Date | Nov 10, 2021 |
About IMCR
Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cance...
Financial Performance
In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.
Financial numbers in millions GBPFinancial StatementsNews
Immunocore announces publication of phase 3 data comparing tebentafusp with investigator's choice in The New England ...
Press Release
Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction ...
PRESS RELEASE
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021
PRESS RELEASE
Immunocore Announces UK's Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization ...
PRESS RELEASE
Immunocore's Eye Cancer Candidate Under Priority Review In US, Europe
The U.S. and European Union regulators have accepted for review Immunocore Holdings Plc's (NASDAQ: IMCR) marketing applications seeking approval for tebentafusp for uveal melanoma (eye cancer). Related:...
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Ap...
PRESS RELEASE
Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update
PRESS RELEASE
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uv...
P RESS RELEASE
Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
PRESS RELEASE
Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
PRESS RELEASE
3 Recent IPO Stocks That Could Be Bigger Winners Than Coinbase
Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.
Immunocore presents phase 3 data comparing tebentafusp with investigator's choice in the clinical trial plenary sessi...
PRESS RELEASE
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary
Newly Listed Immunocore's Tebentafusp Receives Breakthrough Therapy Tag For Eye Cancer
The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...